Pulmonary arterial hypertension (PAH)
Pulmonary arterial hypertension (PAH) counts as a rare disease in Switzerland: Swissmedic has granted 27 orphan drug statuses for this indication. A medicine receives the status when no more than 5 in 10,000 people in Switzerland are affected by the life-threatening or chronically debilitating disease (Art. 4 para. 1 let. a decies TPA).
21 medicines carry a Swissmedic authorisation number for it and 15 companies hold the status. The table below lists every published orphan indication with the date the status was granted.
Orphan designations
Swissmedic publishes one row per medicine and orphan indication: the indication in the wording of the decision, the date the status was granted and, where the status was withdrawn, the withdrawal date. The table below reproduces those rows unchanged and links every indication to the matching rare disease in the directory.
| Orphan indication | Status granted | Status withdrawn |
|---|---|---|
| Pulmonale arterielle Hypertonie | 25/09/2025 | Status active |
| Pulmonale arterielle Hypertonie (PAH) | 08/05/2024 | Status active |
| Traitement à long terme de l'hypertension artérielle pulmonaire (HTAP) chez les patients en classes fonctionelles II à III de l'OMS afin de réduire la morbidité et le risque de mortalité. | 18/12/2023 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie (PAH) | 28/08/2023 | Status active |
| Pulmonale arterielle Hypertonie (PAH) | 11/10/2022 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie | 26/06/2019 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie (PAH) der WHO-Funktionsklasse II und III zur Verbesserung der körperlichen Leistungsfähigkeit bei Erwachsenen. | 27/03/2019 | Status active |
| Langzeitbehandlung von primärer pulmonaler Hypertonie und pulmonal arterieller Hypertonie mit Bindegewebserkrankung bei Patienten mit NYHA III und IV (Einteilung nach der New Yorker Heart Association). | 27/03/2019 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie (PAH) | 18/01/2018 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie (PAH) | 08/09/2016 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie | 12/02/2016 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thrombo-embolischen pulmonalen Hypertonie | 18/08/2015 | Status active |
| pulmonalen arteriellen Hypertonie | 08/10/2013 | Status active |
| Pulmonale arterielle Hypertonie (PAH) | 17/07/2012 | Status active |
| Pulmonale arterielle Hypertonie (PAH) | 17/07/2012 | Status active |
| Hypertension artérielle pulmonaire (WHO class I) | 23/03/2011 | Status active |
| Pulmonal-arterielle Hypertonie | 14/12/2010 | Status active |
| Pulmonale arterielle Hypertonie und idiopathische pulmonale Fibrose | 30/08/2010 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronischen thromboembolischen pulmonalen Hypertonie | 01/07/2010 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronischen thromboembolischen pulmonalen Hypertonie | 01/07/2010 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronischen thromboembolischen pulmonalen Hypertonie | 01/07/2010 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie | 09/02/2009 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thromboembolischen pulmonalen Hypertonie. | 26/09/2007 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thrombo-embolischen pulmonalen Hypertonie | 07/05/2007 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thrombo-embolischen pulmonalen Hypertonie | 07/05/2007 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thromboembolischen pulmonalen Hypertonie | 07/05/2007 | Status active |
| Behandlung der pulmonalen arteriellen Hypertonie und der chronisch thromboembolischen pulmonalen Hypertonie | 07/05/2007 | 25/01/2010 |
Medicines
- AdcircaAuthorised
- Adempas juniorAuthorised
- AdempasAuthorised
- Ambrisentan OrPhaAuthorised
- Bosentan-MephaAuthorised
- Macitentan LemanAuthorised
- Macitentan NOBELAuthorised
- OpsumitAuthorised
- RemodulinAuthorised
- RevatioAuthorised
- RevatioAuthorised
- Sildenafil PAH-MephaAuthorised
- Tadalafil PAH OrPhaAuthorised
- Tadalafil PAH-MephaAuthorised
- TracleerAuthorised
- TracleerAuthorised
- Treprostinil OrPhaAuthorised
- UptraviAuthorised
- VolibrisAuthorised
- WinrevairAuthorised
- YuvanciAuthorised
Reimbursement
Whether compulsory health insurance pays for this medicine depends on the FOPH specialities list (SL). Medicines that are not listed can be reimbursed case by case under Art. 71a-71d KVV.
Care in Switzerland
Switzerland concentrates rare-disease care in the centres recognised by kosek. Patient organisations are networked through ProRaris, and the Orphanet database maintains Swiss entries.
Frequently asked questions
Which medicines with orphan drug status are available in Switzerland for Pulmonary arterial hypertension (PAH)?
Swissmedic lists 21 medicines with orphan drug status for this indication, among them Adcirca, Adempas junior, Adempas, Ambrisentan OrPha, Bosentan-Mepha. The full list with authorisation number and date is in the table on this page.
Does Swiss health insurance cover the treatment?
A medicine is reimbursed once it is on the FOPH specialities list (SL). Without an SL listing, or for use outside the limitation, reimbursement in an individual case under Art. 71a to 71d KVV is possible: the insurer decides after consulting its medical adviser, normally within two weeks.
Where are patients treated in Switzerland?
Care is delivered by the rare-disease centres recognised by kosek at the university and cantonal hospitals. Patient organisations are united in the ProRaris alliance, and diagnoses and reference centres are documented in Orphanet.
Bring your orphan drug to Switzerland
You can enquire about orphan drug status, authorisation and reimbursement in Switzerland. Any specialist service and its scope are agreed separately with the external partner.
- Public Swissmedic data
- Four language versions